Clinical Trials · NCT00765323
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Enrollment
- 169
- Start date
- Sep 2008
- Locations
- 47 sites, 9 countries
- Primary endpoint
- Efficacy based on IGF-1, GH, signs and symptoms scores, tumor size, QoL and Patient Treatment Assessments